Literature DB >> 25927241

Safeguarding genome stability: RASSF1A tumor suppressor regulates BRCA2 at stalled forks.

Dafni Eleftheria Pefani1, Eric O'Neill.   

Abstract

While it has been widely established that defective fork restart after exposure to stress results in increased genomic instability, the importance of fork protection during stalling for safeguarding genomic integrity has recently been fully appreciated. BRCA2, Breast tumor suppressor, has dual functionality promoting not only DNA repair but also preventing DNA lesions at stalled forks. In response to replication stress, BRCA2 recruits RAD51 onto nascent DNA at stalled forks, protecting nascent DNA from nucleolitic cleavage. Phosphorylation of the BRCA2 C-terminal RAD51 binding site by CDK2 promotes RAD51 filament disassembly, leading to nucleolitic cleavage of newly synthesized DNA and compromised fork integrity. Recently we uncovered how the core Hippo pathway components RASSF1A, MST2 and LATS1 regulate CDK2 activity towards BRCA2, in response to fork stalling. In complex with LATS1, CDK2 exhibits reduced kinase activity which results in low levels of pBRCA2-S3291 and stable RAD51 filaments protecting nascent DNA from MRE11 cleavage. In the absence of the RASSF1A/MST2/LATS1/CDK2 pathway increased resection of newly synthesized DNA leads to chromosomal instability and malignant transformation. This function of RASSF1A in stalled replication fork protection adds to the role of RASSF1A as a tumor suppressor and builds up evidence for RASSF1A status and its prognostic and predictive value in cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25927241      PMCID: PMC4613848          DOI: 10.1080/15384101.2015.1035845

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  65 in total

1.  Role of BRCA2 in control of the RAD51 recombination and DNA repair protein.

Authors:  A A Davies; J Y Masson; M J McIlwraith; A Z Stasiak; A Stasiak; A R Venkitaraman; S C West
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

2.  Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.

Authors:  R Dammann; G Yang; G P Pfeifer
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

3.  RASSF1A polymorphism in familial breast cancer.

Authors:  J Bergqvist; A Latif; S A Roberts; K D Hadfield; F Lalloo; A Howell; D G Evans; W G Newman
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

4.  RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency.

Authors:  Abdelbaset Buhmeida; Adnan Merdad; Judah Al-Maghrabi; Joudah El-Maghrabi; Fatima Al-Thobaiti; Manar Ata; Ayman Bugis; Kari Syrjänen; Adel Abuzenadah; Adeel Chaudhary; Mamdooh Gari; Mohammed Al-Qahtani; Ashraf Dallol
Journal:  Anticancer Res       Date:  2011-09       Impact factor: 2.480

5.  Tumor susceptibility of Rassf1a knockout mice.

Authors:  Stella Tommasi; Reinhard Dammann; Zhongqiu Zhang; Yian Wang; Limin Liu; Walter M Tsark; Sharon P Wilczynski; Jie Li; Ming You; Gerd P Pfeifer
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

6.  A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast.

Authors:  Undraga Schagdarsurengin; Claudia Seidel; Eva J Ulbrich; Heinz Kölbl; Jürgen Dittmer; Reinhard Dammann
Journal:  Int J Oncol       Date:  2005-07       Impact factor: 5.650

7.  Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair.

Authors:  Eva Petermann; Manuel Luís Orta; Natalia Issaeva; Niklas Schultz; Thomas Helleday
Journal:  Mol Cell       Date:  2010-02-26       Impact factor: 17.970

8.  Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.

Authors:  Sofia Honorio; Angelo Agathanggelou; Marcus Schuermann; Wulf Pankow; Paolo Viacava; Eamonn R Maher; Farida Latif
Journal:  Oncogene       Date:  2003-01-09       Impact factor: 9.867

9.  The RecQ helicase WRN is required for normal replication fork progression after DNA damage or replication fork arrest.

Authors:  Julia M Sidorova; Nianzhen Li; Albert Folch; Raymond J Monnat
Journal:  Cell Cycle       Date:  2008-01-04       Impact factor: 4.534

10.  RAD51- and MRE11-dependent reassembly of uncoupled CMG helicase complex at collapsed replication forks.

Authors:  Yoshitami Hashimoto; Fabio Puddu; Vincenzo Costanzo
Journal:  Nat Struct Mol Biol       Date:  2011-12-04       Impact factor: 15.369

View more
  4 in total

1.  High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.

Authors:  Ann Christin Parplys; Jasna Irena Seelbach; Saskia Becker; Matthias Behr; Agnieszka Wrona; Camilla Jend; Wael Yassin Mansour; Simon Andreas Joosse; Horst-Werner Stuerzbecher; Helmut Pospiech; Cordula Petersen; Ekkehard Dikomey; Kerstin Borgmann
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.

Authors:  Jana Jeschke; Martin Bizet; Christine Desmedt; Emilie Calonne; Sarah Dedeurwaerder; Soizic Garaud; Alexander Koch; Denis Larsimont; Roberto Salgado; Gert Van den Eynden; Karen Willard Gallo; Gianluca Bontempi; Matthieu Defrance; Christos Sotiriou; François Fuks
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 3.  The MRE11-RAD50-NBS1 Complex Conducts the Orchestration of Damage Signaling and Outcomes to Stress in DNA Replication and Repair.

Authors:  Aleem Syed; John A Tainer
Journal:  Annu Rev Biochem       Date:  2018-04-25       Impact factor: 23.643

Review 4.  Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?

Authors:  Stephanie McKenna; Lucía García-Gutiérrez
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.